多变量疾病特异性模型提升默克尔细胞癌预后预测
该国际队列研究纳入2000至2020年10958例组织学确诊的默克尔细胞癌患者,比较疾病特异性死亡与总生存的区分度,并构建多变量Fine-Gray竞争风险模型。结果显示疾病特异性死亡区分度更优,纳入躯干病灶、年龄>84岁、男性及婚姻状态后,模型预测能力优于现有分期系统。
要点
- 疾病特异性死亡比总生存更适合作为MCC分期的分层终点。
- 躯干病灶、年龄>84岁、男性及婚姻状态是疾病特异性死亡的独立预测因素。
- 多变量模型在美國队列C-index 0.75 vs 0.64,英国外部验证队列C-index 0.77。
核心结论
- MCC分期对疾病特异性死亡的区分优于总生存。
- 纳入患者和肿瘤特征的多变量模型可提升预后预测能力。
研究设计与样本
- 数据来自美国队列和英国外部验证队列。
- 采用多变量Fine和Gray竞争风险模型。
主要发现
- 疾病特异性死亡作为生存终点比总生存具有更高区分度。
- 躯干病灶的亚分布风险比为1.96(P < .001)。
- 年龄>84岁的亚分布风险比为1.79(P < .001)。
- 男性的亚分布风险比为1.34(P < .001)。
- 婚姻状态的亚分布风险比为1.09(P < .001)。
关键数值与推荐
- 多变量模型在美国队列的C-index为0.75,现有分期为0.64(P < .001)。
- 多变量模型在英国外部验证队列的C-index为0.77。
临床怎么用
- 临床预后评估可优先采用疾病特异性死亡作为终点。
- 在现有分期基础上纳入躯干病灶、年龄>84岁、男性及婚姻状态以优化风险分层。
局限性
- 回顾性研究设计。
- 外部验证仅来自英国队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Merkel cell carcinoma (MCC) is a highly aggressive cutaneous malignancy for which accurate prognostication is necessary to support clinical management. OBJECTIVE: (1) To determine which survival endpoint-disease-specific death (DSD) or overall survival (OS)-was better stratified by MCC American Joint Cancer Committee eighth edition staging. (2) To develop a multivariable model for enhanced MCC survival predictions. METHODS: A retrospective analysis of 10,958 histologically confirmed MCC patients between January 2000 and December 2020 was performed. Patient and tumor features were analyzed from 2 cohorts: a US cohort and an external validation UK cohort. A multivariable Fine and Gray competing risk (FG) model was utilized to account for the competing risk. RESULTS: DSD demonstrated greater discriminatory power as a survival endpoint when compared with OS. Multivariate FG analysis identified the most impactful features of DSD: truncal lesions (subdistribution hazard ratios [SHRs] = 1.96, P < .001), age >84 years (SHR = 1.79, P < .001), male sex (SHR = 1.34, P < .001), and marital status (SHR = 1.09, P < .001). A second FG model incorporating those impactful features enhanced survival predictions beyond current MCC staging criteria alone in both the US (C-index 0.75 vs 0.64, P < .001) and external validation UK cohort (C-index 0.77). CONCLUSIONS: MCC staging can stratify DSD better than OS. Additional patient and tumor features enhanced prognostication beyond current staging systems.
引用
- Andrew TW, Erdmann S, Alrawi M, et al. A multivariable disease-specific model enhances prognostication beyond current Merkel cell carcinoma staging: An international cohort study of 10,958 patients. J Am Acad Dermatol. 2024. PMID: 39577698. doi:10.1016/j.jaad.2024.10.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。